Drinabant

Last updated
Drinabant
Drinabant.svg
Drinabant ball-and-stick model.png
Clinical data
ATC code
  • None
Identifiers
  • (±)-N-{1-[Bis(4-chlorophenyl)methyl]-3-azetidinyl}-N-(3,5-difluorophenyl)methanesulfonamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C23H20Cl2F2N2O2S
Molar mass 497.38 g·mol−1
3D model (JSmol)
  • Fc1cc(cc(F)c1)N(C4CN(C(c2ccc(Cl)cc2)c3ccc(Cl)cc3)C4)S(=O)(=O)C
  • InChI=1S/C23H20Cl2F2N2O2S/c1-32(30,31)29(21-11-19(26)10-20(27)12-21)22-13-28(14-22)23(15-2-6-17(24)7-3-15)16-4-8-18(25)9-5-16/h2-12,22-23H,13-14H2,1H3
  • Key:IQQBRKLVEALROM-UHFFFAOYSA-N

Drinabant (INN; AVE-1625) is a drug that acts as a selective CB1 receptor antagonist, which was under investigation varyingly by Sanofi-Aventis as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence. [1] [2] [3] Though initially studied as a potential treatment for a variety of different medical conditions, Sanofi-Aventis eventually narrowed down the therapeutic indications of the compound to just appetite suppression. Drinabant reached phase IIb clinical trials for this purpose in the treatment of obesity but was shortly thereafter discontinued, [4] likely due to the observation of severe psychiatric side effects including anxiety, depression, and thoughts of suicide in patients treated with the now-withdrawn CB1R antagonist rimonabant. [5]

In late 2018, the drug was licensed by Opiant Pharmaceuticals, which intends to develop it for the treatment of acute cannabinoid overdose (ACO) as an injectable for administration in an emergency department setting. Opiant claims that ACO is most frequently linked to the ingestion of cannabis edibles and/or synthetic cannabinoids that are more potent and less expensive than natural cannabis extracts such as hashish. Edibles, sold as capsules, brownies, cookie s, chocolate bar s and gumdrops, may pose particular risks for children, who may consume these by accident.[ citation needed ] The existence of ACO is heavily debated. In fact, most people who die from cannabinoid ingestion have had chronic life-long heart problems or are involved in accidents from driving while intoxicated. [6]

Rimonabant was another cannabinoid receptor antagonist developed for prescription drug use that triggered severe psychiatric side effects and was withdrawn from the market.

See also

References

  1. ↑ Lange JH, Kruse CG (2008). "Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives". The Chemical Record. 8 (3): 156–68. doi:10.1002/tcr.20147. PMID   18563799.
  2. ↑ Kwon MO, Herrling P (2005). "List of drugs in development for neurodegenerative diseases. Update September 2005". Neuro-Degenerative Diseases. 2 (2): 61–108. doi:10.1159/000089285. PMID   16909049. S2CID   2553974.
  3. ↑ Gerald Litwack (14 August 2009). Anandamide. Academic Press. p. 172. ISBN   978-0-12-374782-2 . Retrieved 13 May 2012.
  4. ↑ Reggio, Patricia H. (2009). "Toward the design of cannabinoid CB1 receptor inverse agonists and neutral antagonists". Drug Development Research. 70 (8): 585–600. doi:10.1002/ddr.20337. ISSN   0272-4391. S2CID   83478850.
  5. ↑ Lee HK, Choi EB, Pak CS (2009). "The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents". Current Topics in Medicinal Chemistry. 9 (6): 482–503. doi:10.2174/156802609788897844. PMID   19689362. Archived from the original on 2013-05-22. Retrieved 2019-07-29.
  6. ↑ Suriaga, Armiel; Tappen, Ruth M; Aston, Elizabeth R; Chiang-Hanisko, Lenny; Newman, David (2023). "Cannabinoids and synthetic cannabinoids as a cause of death: Characteristics, manner of deaths, trends, and their healthcare implications". Journal of Nursing Scholarship. 55 (3): 623–636. doi:10.1111/jnu.12817. PMC   11537499 . PMID   36250599.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.